Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Beraprost. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 4/20 | 0.85 |
| ▸ | PTGER3 | P43115 | 13/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.39 |
| ▸ | PTGFR | P43088 | 12/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beraprost SCHEMBL4754472 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL11946708 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL1554142 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16904620 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL4754473 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL6084946 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL16894023 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL22972690 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL21778834 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR | |
| Beraprost SCHEMBL19113984 | 1.00 | PTGIR (0.85) | PTGIRPTGER3PTGER2PTGER1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150308-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROM | CHIROGATE INTERNATIONAL INC. (TW) | 2024-05-09 | — | — | US | disclosed |
| CN-109219601-B | Method for preparing optically active beraprost | 奇诺因药物和化学工厂私人有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20200171026-A1 | PROSTACYCLIN RECEPTOR AGONISTS FOR REDUCTION OF BODY FAT | ALLERGAN INC (US) | 2020-06-04 | — | — | US | disclosed |
| EP-3656767-A1 | BERAPROST-314D MONOHYDRATE CRYSTALS AND METHODS FOR PREPARATION THEREOF | Chirogate International Inc. (TW) | 2020-05-27 | — | — | EP | disclosed |
| US-10421737-B2 | Process for the preparation of optically active Beraprost | CHINOIN PHARMACEUTICAL AND CHEMICAL WORKS PRIVATE COMPANY LTD. (HU) | 2019-09-24 | — | — | US | disclosed |
| US-9388154-B2 | Process for preparing synthetic prostacyclins | Lund Biotechnology PBC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388154-B2 | Process for preparing synthetic prostacyclins | Lund Biotechnology PBC (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150025255-A1 | PROCESS FOR PREPARING SYNTHETIC PROSTACYCLINS | LUNG BIOTECHNOLOGY INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025255-A1 | PROCESS FOR PREPARING SYNTHETIC PROSTACYCLINS | LUNG BIOTECHNOLOGY INC. (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171026-A1 | PROSTACYCLIN RECEPTOR AGONISTS FOR REDUCTION OF BODY FAT | PTGIR, PTGER1, PTGDR | PTGIR 1/4885PTGER3 10/4885PTGER2 5/4885 |
| US-10421737-B2 | Process for the preparation of optically active Beraprost | CYP51A1, DDOST, SQLE | PTGIR 189/4885PTGER3 762/4885PTGER2 521/4885 |
| US-20150025255-A1 | PROCESS FOR PREPARING SYNTHETIC PROSTACYCLINS | PTGIS, PTGIR, PTGES | PTGIR 2/4885PTGER3 21/4885PTGER2 11/4885 |
| US-20240150308-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF BENZOPROSTACYCLIN ANALOGUES AND BENZOPROSTACYCLIN ANALOGUES PREPARED THEREFROM | PTGIS, PTGIR, PTGES | PTGIR 2/4885PTGER3 24/4885PTGER2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.